Pebc Pharmacist Practice Test
Free · 140 Questions.

Question 1

According to Diabetes Canada clinical practice guidelines, what is the first-line initial pharmacotherapy of choice for most adult patients diagnosed with Type 2 Diabetes Mellitus (in conjunction with lifestyle management)?

• A. Meglitinide (e.g. repaglinide), under standard rules, under standard rules.
• B. Metformin (unless contraindicated or not tolerated), following safety rules.
• C. Sulfonylurea (e.g. gliclazide), following safety rules, as required by law.
• D. Basal insulin glargine, under established operating protocols.

Explanation: Diabetes Canada guidelines recommend Metformin as the initial first-line glucose-lowering therapy due to its proven efficacy, low hypoglycemia risk, weight neutrality, and long-term safety data.

Question 2

In patients with Type 2 Diabetes and established Atherosclerotic Cardiovascular Disease (ASCVD), which classes of antihyperglycemic agents have proven cardiovascular benefit and should be prioritized?

• A. Alpha-glucosidase inhibitors (e.g. acarbose) exclusively, under established provincial operating and compliance protocols, under authorized rules.
• B. SGLT2 inhibitors (e.g. empagliflozin, dapagliflozin) or GLP-1 receptor agonists (e.g. semaglutide, liraglutide).
• C. Sulfonylureas and DPP-4 inhibitors, following standard statutory compliance and regulatory procedures, under authorized rules.
• D. Thiazolidinediones (e.g. pioglitazone) and Meglitinides, pursuant to governing provincial legislation and regulatory guidelines.

Explanation: SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated significant reductions in major adverse cardiovascular events (MACE), cardiovascular mortality, and heart failure hospitalizations in randomized controlled trials.

Question 3

According to Hypertension Canada guidelines, which four drug classes are recommended as first-line monotherapy or initial single-pill combination therapy for uncomplicated essential hypertension in adults?

• A. ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Dihydropyridine Calcium Channel Blockers (CCBs), and Thiazide/Thiazide-like diuretics.
• B. Direct renin inhibitors and Aldosterone antagonists, following standard statutory compliance and regulatory procedures.
• C. Centrally acting alpha-2 agonists and Potassium-sparing diuretics only, pursuant to governing provincial legislation and regulatory guidelines.
• D. Beta-blockers, Alpha-blockers, Loop diuretics, and Direct vasodilators, in accordance with applicable regulatory and safety standards, under standard rules.

Explanation: Hypertension Canada recommends ACE inhibitors, ARBs, CCBs, and thiazide/thiazide-like diuretics (e.g. chlorthalidone, indapamide) as first-line agents due to proven cardiovascular morbidity and mortality reduction.

Question 4

Why is the concurrent combination of an ACE Inhibitor (e.g. ramipril) and an Angiotensin Receptor Blocker (e.g. losartan) strictly NOT recommended in hypertension and heart failure management?

• A. Dual renin-angiotensin blockade significantly increases the risk of severe hyperkalemia, acute kidney injury, and hypotension without clinical benefit.
• B. The combination causes rapid irreversible hepatic necrosis within 48 hours, pursuant to governing provincial legislation and regulatory guidelines.
• C. Dual therapy causes severe hypokalemia and cardiac QT prolongation, in accordance with applicable regulatory and safety standards, under official standards.
• D. The two classes completely neutralize each other's therapeutic activity in the liver, under established provincial operating and compliance protocols.

Explanation: Large clinical trials (ONTARGET, ALTITUDE) demonstrated that dual renin-angiotensin system (RAS) blockade causes higher rates of renal failure and hyperkalemia without improving cardiovascular survival.

Question 5

According to the Canadian Cardiovascular Society (CCS) Heart Failure guidelines, which four guideline-directed medical therapy (GDMT) drug classes ('The Four Pillars') improve survival in Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%)?

• A. Alpha-blocker, Centrally-acting agonist, Potassium supplement, and Antiarrhythmic, following standard statutory rules.
• B. Loop diuretic, Digoxin, Nitrate, and Hydralazine, in accordance with applicable regulatory and safety standards, in compliance with law.
• C. Dihydropyridine CCB, Statin, Aspirin, and Warfarin, under established provincial operating and compliance protocols.
• D. ARNI/ACEi/ARB, Evidence-based Beta-blocker, Mineralocorticoid Receptor Antagonist (MRA), and SGLT2 inhibitor.

Explanation: The 4 foundational pillars of HFrEF GDMT proven to reduce mortality and hospitalization are: 1. ARNI (sacubitril/valsartan) or ACEi/ARB, 2. Beta-blocker (carvedilol, bisoprolol, metoprolol succinate), 3. MRA (spironolactone/eplerenone), and 4. SGLT2i (dapagliflozin/empagliflozin).